CERUS CORP CERS

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

We are a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on our proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Our INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex, or IFC, and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received a broad range of regulatory approvals and certification, including but not limited to FDA approval in the U.S., CE Certificates of Conformity delivered in accordance with the Medical Devices Regulation 2017/745, or MDR, permitting us to affix the CE Mark to our products and place them on the market in the European Union and other jurisdictions that recognize the CE Mark, and are being marketed and sold in a number of countries around the world, including the U.S., certain countries in Europe, the Commonwealth of Independent States, or CIS, the Middle East, and Latin America and selected countries in other regions of the world. Additionally, we have received FDA approval for the INTERCEPT Blood System for Cryoprecipitation. The INTERCEPT Blood System for Cryoprecipitation uses our plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced. We currently sell the platelet and plasma systems using our direct sales force and through distributors and sell IFC or disposable kits to manufacture IFC in the U.S. using our direct sales force. If we are unable to gain or maintain widespread commercial adoption in markets where our blood safety products are approved for commercialization, including in the U.S., we will have difficulties achieving and maintaining profitability.

Last close 2.33 2026-10-23
Market cap $469.6M 2026-06-30 share count
52-week range 1.38 - 3.47

Valuation FY2025 figures against the last close

P/S2.0x
P/E—
P/FCF423.8x
EV/EBITDA—
Dividend yield—
Diluted EPS-0.08

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $233.8M$201.3M$186.8M$188.3M$159.5M$114.2M$93.8M$76.1M$51.3M$39.3M
Cost of revenue —————$41.2M$33.4M$31.6M$22.5M$20.3M
Gross profit —————$73.1M$60.4M$44.4M$28.8M$16.9M
SG&A $80.9M$75.9M$75.5M$83.3M$81.3M$67.0M$66.2M$56.8M$52.6M$49.0M
Total operating expenses $148.6M$134.8M$146.9M$147.4M$145.0M$131.4M$126.6M$99.4M$86.3M$80.4M
Operating income -$8.7M-$14.2M-$30.1M-$34.1M-$48.9M-$58.3M-$66.2M-$55.0M-$57.5M-$61.4M
Interest expense $8.3M$8.9M$8.4M$5.8M$4.9M$3.7M$6.1M$4.0M$3.0M$2.4M
Pre-tax income -$15.3M-$20.8M-$37.3M-$42.3M-$54.1M-$59.6M-$71.0M-$57.3M-$56.7M-$62.7M
Income tax $354.0K$205.0K$325.0K$488.0K$319.0K$284.0K$263.0K$229.0K$3.9M$175.0K
Net income -$15.6M-$21.0M-$37.6M-$42.8M-$54.4M-$59.9M-$71.2M-$57.6M-$60.6M-$62.9M
EPS, basic -0.08-0.11-0.21-0.24-0.32-0.37—-0.44-0.56-0.62
EPS, diluted -0.08-0.11-0.21-0.24-0.32-0.37-0.51-0.44-0.56-0.62
Shares, diluted (wtd. avg.) 190.6M184.6M180.3M176.5M171.3M163.9M139.8M131.7M108.2M101.8M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $20.0M$20.3M$13.4M$37.4M$51.0M$38.9M$37.4M$31.6M$13.9M$22.7M
Short-term investments $62.9M$60.2M$54.2M$66.6M$80.6M$97.0M$50.7M$88.7M$47.0M$45.1M
Receivables $30.4M$29.8M$35.5M$34.4M$25.1M$21.2M$16.9M$8.8M$12.4M$6.9M
Inventory $56.1M$38.1M$39.9M$29.0M$26.8M$23.3M$19.5M$13.5M$14.5M$12.5M
Total current assets $174.4M$152.0M$144.4M$170.1M$187.1M$183.4M$128.1M$146.9M$89.9M$94.1M
Property, plant and equipment $9.2M$7.2M$8.6M$11.0M$12.2M$13.9M$14.9M$8.1M$2.1M$3.0M
Goodwill $1.3M$1.3M$1.3M$1.3M$1.3M$1.3M$1.3M$1.3M$1.3M$1.3M
Other intangibles ——————$132.0K$334.0K$536.0K$738.0K
Total assets $221.9M$200.9M$197.7M$218.1M$237.5M$221.4M$165.5M$163.5M$98.2M$103.5M
Accounts payable $28.0M$21.7M$23.8M$33.0M$35.6M$24.2M$22.2M$18.6M$11.0M$8.6M
Total current liabilities $100.8M$63.6M$67.5M$117.1M$78.6M$60.0M$50.3M$52.7M$23.1M$26.9M
Total liabilities $156.9M$144.0M$144.3M$149.5M$151.9M$117.6M$108.5M$78.9M$59.3M$45.7M
Retained earnings -$1.08B-$1.07B-$1.04B-$1.01B-$964.3M-$910.0M-$850.1M-$778.9M-$721.3M-$660.7M
Total equity $64.2M$56.1M$53.4M$68.6M$85.6M$103.8M$57.1M$84.5M$38.9M$57.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $4.8M$11.4M-$43.2M-$25.6M-$33.9M-$41.8M-$65.5M-$31.2M-$52.2M-$53.5M
Depreciation and amortisation $1.4M$1.9M$2.6M$3.0M$3.1M$3.1M$2.4M$1.4M$1.8M$1.8M
Stock-based compensation $22.9M$22.9M$20.3M$24.5M$23.6M$18.0M$13.3M$10.4M$9.4M$8.1M
Capital expenditure $3.7M$2.8M$4.6M$2.0M$910.0K$1.6M$8.9M$1.1M$353.0K$563.0K
Investing cash flow -$6.2M-$8.1M$8.6M$8.5M$12.7M-$49.6M$28.2M-$43.8M$421.0K-$19.9M
Financing cash flow $231.0K$5.0M$10.7M$4.2M$34.3M$91.8M$43.5M$92.8M$43.0M$24.6M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001020214-26-000011.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -100M 0 100M 200M 300M Revenue, FY2016: 39.3M Gross profit, FY2016: 16.9M Net income, FY2016: -62.9M Revenue, FY2017: 51.3M Gross profit, FY2017: 28.8M Net income, FY2017: -60.6M Revenue, FY2018: 76.1M Gross profit, FY2018: 44.4M Net income, FY2018: -57.6M Revenue, FY2019: 93.8M Gross profit, FY2019: 60.4M Net income, FY2019: -71.2M Revenue, FY2020: 114.2M Gross profit, FY2020: 73.1M Net income, FY2020: -59.9M Revenue, FY2021: 159.5M Net income, FY2021: -54.4M Revenue, FY2022: 188.3M Net income, FY2022: -42.8M Revenue, FY2023: 186.8M Net income, FY2023: -37.6M Revenue, FY2024: 201.3M Net income, FY2024: -21M Revenue, FY2025: 233.8M Net income, FY2025: -15.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $39.3M $51.3M $76.1M $93.8M $114.2M $159.5M $188.3M $186.8M $201.3M $233.8M
Gross profit $16.9M $28.8M $44.4M $60.4M $73.1M — — — — —
Net income -$62.9M -$60.6M -$57.6M -$71.2M -$59.9M -$54.4M -$42.8M -$37.6M -$21.0M -$15.6M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%